Analysis of treatment outcome and influencing factors of Tibetan tuberculosis patients in Qinghai Province
-
摘要:
目的 分析青海省藏族人群结核病治疗转归及影响因素,为藏族结核病的防治提供参考。 方法 回顾性分析2016―2020年青海省藏族人群结核病治疗转归情况,采用Cochran-Armitage趋势检验分析成功治疗率随时间变化的趋势,χ2检验初步筛选可能的影响因素,采用多因素logistic回归分析模型进行影响因素分析,方差膨胀系数(variance inflation factor, VIF)检验共线性。 结果 2016―2020年青海省藏族人群肺结核成功治疗率为96.841%,成功治疗率呈上升趋势。多因素logistic回归分析模型显示,年龄≥60岁(OR=2.467, 95% CI: 1.333~4.889, P=0.006)、就诊延迟(OR=1.364, 95% CI: 1.096~1.702, P=0.006)、Ⅲ型结核病(OR=2.659, 95% CI: 1.190~7.584, P=0.034)、Ⅳ型结核病(OR=4.457, 95% CI: 1.921~12.988, P=0.002)、Ⅴ型结核病(OR=4.671, 95% CI: 1.976~13.747, P=0.001)和复治(OR=1.868, 95% CI: 1.219~2.763, P=0.003)为不良结局的危险因素,流动人口(OR=0.603, 95% CI: 0.453~0.794, P<0.001)、疾病预防控制机构管理(OR=0.211, 95% CI: 0.081~0.661, P=0.003)、医院管理(OR=0.313, 95% CI: 0.125~0.962, P=0.023)、全程管理(OR=0.146, 95% CI: 0.100~0.213, P<0.001)、强化期督导(OR=0.543, 95% CI: 0.373~0.795, P=0.002)和全程督导(OR=0.374, 95% CI: 0.252~0.556, P<0.001)为保护因素。 结论 青海省藏族结核病成功治疗率较高,重点关注老年患者、就诊延迟患者、Ⅲ型结核病患者、Ⅳ型结核病患者、Ⅴ型结核病患者和复治患者;提高基层医疗机构的结核病治疗管理能力,采取督导和全程管理的治疗管理方式,以进一步提高成功治疗率。 Abstract:Objective This study aims to analyze the treatment outcomes and contributing factors of Tibetan tuberculosis (TB) patients in Qinghai Province, offering a reference point for future prevention and treatment strategies. Methods A retrospective analysis of the treatment outcomes of Tibetan TB patients in Qinghai Province was conducted for the period of 2016 to 2020. The Cochran-Armitage trend test was used to analyze the successful treatment rate over time. The Chi-square test was utilized for an initial screening of potential contributing factors. Multiple logistic regression analysis was employed to further examine these factors, with multicollinearity tested using the variance inflation factor. Results The successful treatment rate of Tibetan tuberculosis patients in Qinghai Province from 2016 to 2020 was 96.841%, exhibiting an upward trend. Multiple logistic regression showed the age group of ≥60 years (OR=2.467, 95% CI: 1.333-4.889, P=0.006), delay in health-care seeking (OR=1.364, 95% CI: 1.096-1.702, P=0.006), type Ⅲ (OR=2.659, 95% CI: 1.190-7.584, P=0.034), type Ⅳ (OR=4.457, 95% CI: 1.921-12.988, P=0.002), type Ⅴ (OR=4.671, 95% CI: 1.976-13.747, P=0.001) and retreatment (OR=1.868, 95% CI: 1.219-2.763, P=0.003) were risk factors for outcomes. Floating population (OR=0.603, 95% CI: 0.453-0.794, P < 0.001), managed by disease control and prevention centers (OR=0.211, 95% CI: 0.081-0.661, P=0.003), hospital management (OR=0.313, 95% CI: 0.125-0.962, P=0.023), entire course management (OR=0.146, 95% CI: 0.100-0.213, P < 0.001), intensive term supervision (OR=0.543, 95% CI: 0.373-0.795, P=0.002) and entire course supervision (OR=0.374, 95% CI: 0.252-0.556, P < 0.001) were protective factors. Conclusions The treatment outcomes for Tibetan TB patients in Qinghai Province were encouraging. However, more attention should be given to elderly patients, those who delay seeking healthcare, patients categorized as type Ⅲ, Ⅳ, Ⅴ, and those undergoing retreatment. It is crucial to enhance TB treatment and management capacity in primary healthcare institutions and implement a supervised, full-course treatment management approach to boost the successful treatment rate. -
Key words:
- Tibetan /
- Tuberculosis /
- Treatment outcome /
- Influencing factors
-
表 1 青海省2016―2020年藏族人群结核病治疗转归情况
Table 1. The treatment outcome of Tibetan tuberculosis in Qinghai Province from 2016 to 2020
年份
Year治疗例数
Number of treatment cases成功治疗Successful treatment 不良结局Adverse outcome 治愈Cure 完成疗程
Treatment completed合计
Total失败Failure 死亡
Death不良反应
Adverse reaction失访
Missing其他
Other合计
Total2016 1 289 185(14.352) 1 032(80.062) 1 217(94.414) 9(0.698) 10(0.776) 25(1.939) 7(0.543) 21(1.629) 72(5.586) 2017 1 928 185(9.595) 1 627(84.388) 1 812(93.983) 5(0.259) 9(0.467) 25(1.297) 12(0.622) 65(3.371) 116(6.017) 2018 2 528 365(14.438) 2 087(82.555) 2 452(96.994) 7(0.277) 10(0.396) 12(0.475) 16(0.633) 31(1.226) 76(3.006) 2019 3 605 554(15.368) 2 968(82.330) 3 522(97.698) 10(0.277) 27(0.749) 12(0.333) 5(0.139) 29(0.804) 83(2.302) 2020 2 364 467(19.755) 1 874(79.272) 2 341(99.027) 3(0.127) 4(0.169) 7(0.296) 1(0.042) 8(0.338) 23(0.973) 合计Total 11 714 1 756(14.991) 9 588(81.851) 11 344(96.841) 34(0.290) 60(0.512) 81(0.691) 41(0.350) 154(1.315) 370(3.159) 表 2 青海省2016―2020年藏族人群结核病治疗转归多因素logistic回归分析
Table 2. Multivariate logistic regression analysisof treatment outcome for Tibetan tuberculosis among Tibetan population in Qinghai Province from 2016 to 2020
因素Factor β sx Wald值
Wald valueOR值(95% CI)
OR value (95% CI)P值
P value年龄组/岁Age group /years <14 1.000 14~<45 0.160 0.301 0.283 1.174(0.675~2.220) 0.595 45~<60 0.329 0.330 0.993 1.389(0.749~2.755) 0.319 ≥60 0.903 0.329 7.527 2.467(1.333~4.889) 0.006 职业Occupation 非农牧民Non agro-pastoralist 1.000 农牧民Agro-pastoralist 0.217 0.136 2.539 1.243(0.955~1.631) 0.111 流动人口Transient population 非流动人口Not transient population 1.000 流动人口Transient population -0.506 0.143 12.489 0.603(0.453~0.794) < 0.001 患者来源Patient source 其他Other 1.000 检查发现Examination revealed -0.480 1.206 0.158 0.619(0.071~13.235) 0.691 督促就诊Urge medical treatment -0.551 1.062 0.270 0.576(0.107~10.722) 0.604 主动就诊Active visiting -0.326 1.054 0.096 0.722(0.137~13.328) 0.757 就诊延迟Health-care seeking delay 无就诊延迟Not health-care seeking delay 1.000 就诊延迟Health-care seeking delay 0.310 0.112 7.641 1.364(1.096~1.702) 0.006 诊断分型Diagnosis and classification Ⅰ型Model Ⅰ 1.000 Ⅱ型Model Ⅱ 0.904 0.506 3.190 2.469(0.986~7.491) 0.074 Ⅲ型Model Ⅲ 0.978 0.462 4.474 2.659(1.190~7.584) 0.034 Ⅳ型Model Ⅳ 1.495 0.477 9.801 4.457(1.921~12.988) 0.002 Ⅴ型Model Ⅴ 1.541 0.484 10.122 4.671(1.976~13.747) 0.001 现管理单位性质The property of the current management unit 基层医疗机构Primary medical institutions 1.000 疾病预防控制机构Disease control institutions -1.558 0.525 8.799 0.211(0.081~0.661) 0.003 医院Hospitals -1.163 0.512 5.160 0.313(0.125~0.962) 0.023 治疗分类Treatment classification 初治Initial treatment 1.000 复治Repeated treatment 0.625 0.208 9.019 1.868(1.219~2.763) 0.003 实际治疗管理方案Actual treatment management plan 自服药Self-administered 1.000 全程管理Whole course management -1.927 0.191 101.770 0.146(0.100~0.213) < 0.001 强化期督导Intensify phase direct -0.610 0.193 10.051 0.543(0.373~0.795) 0.002 全程督导Whole course supervision -0.985 0.202 23.840 0.374(0.252~0.556) < 0.001 -
[1] 梁达, 商越, 赵晓银, 等. 青海省2014-2019年肺结核流行特征及预测模型比较研究[J]. 医学动物防制, 2021, 37(4): 313-318. DOI: 10.7629/yxdwfz202104002.Liang D, Shang Y, Zhao XY, et al. Epidemiological characteristics and comparative study of prediction model for pulmonary tuberculosis in Qinghai Province from 2014 to 2019[J]. J Med Pest Control, 2021, 37(4): 313-318. DOI: 10.7629/yxdwfz202104002. [2] 魏於家, 马斌忠, 王朝才, 等. 青海省藏族初治涂阳肺结核患者治疗转归情况及影响因素[J]. 中华疾病控制杂志, 2020, 24(3): 284-289. DOI: 10.16462/j.cnki.zhjbkz.2020.03.008.Wei YJ, Ma BZ, Wang ZC, et al. Analysis on the factors that influence the treatment outcome of Tibetan nationality new smear-positive pulmonary tuberculosis patients in Qinghai Province[J]. Chin J Dis Control Prev, 2020, 24(3): 284-289. DOI: 10.16462/j.cnki.zhjbkz.2020.03.008. [3] 马斌忠, 饶华祥, 蒋明霞, 等. 青海省新发涂阳肺结核病人治疗转归分析[J]. 医学动物防制, 2019, 35(9): 817-821. DOI: 10.7629/yxdwfz201909001.Ma BZ, Rao HX, Jiang MX, et al. Analysis of treatment outcome of new smear positive pulmonary tuberculosis cases in Qinghai Province[J]. J Med Pest Contrl, 2019, 35(9): 817-821. DOI: 10.7629/yxdwfz201909001. [4] 赵雁林, 陈明亭. 中国结核病防治工作技术指南[M]. 北京: 人民卫生出版社, 2021: 12-17, 48-49, 77-78, 228-229.Zhao YL, Chen MT. Technical Guidelines for Tuberculosis Control and Prevention in China[M]. Beijing: Peoples Medical Publishing House, 2021: 12-17, 48-49, 77-78, 228-229. [5] Cohen DB, Meghji J, Squire SB. A systematic review of clinical outcomes on the WHO Category Ⅱ retreatment regimen for tuberculosis[J]. Int J Tuberc Lung Dis, 2018, 22(10): 1127-1134. DOI: 10.5588/ijtld.17.0705. [6] 蒋明霞, 王兆芬, 马斌忠, 等. 青海省利福平耐药/耐多药肺结核流行特征分析[J]. 疾病监测, 2022, 37(3): 401-404. DOI: 10.3784/jbjc.202104290235.Jiang MX, Wang ZF, Ma BZ, et al. Epidemiological characteristics of rifampicin-resistant and multidrug-resistant tuberculosis in Qinghai[J]. Dis Surveillance, 2022, 37(3): 401-404. DOI: 10.3784/jbjc.202104290235. [7] 上海市感染性疾病(结核病)临床医学研究中心/同济大学附属上海市肺科医院, 首都医科大学附属北京胸科医院/北京市结核病胸部肿瘤研究所, 中国防痨协会《中国防痨杂志》编辑委员会. 复治肺结核病诊断和治疗专家共识[J]. 中国防痨杂志, 2021, 43(12): 1226-1238. DOI: 10.3969/j.issn.1000-6621.2021.12.002.Shanghai Clinical Medical Research Center of Infectious Diseases (Tuberculosis)/Shanghai Pulmonary Hospital Affiliated to Tongji University, Beijing Chest Hospital Affiliated to Capital Medical University/Beijing Institute of Tuberculosis and Chest Cancer, Editorial Committee of the Journal of Tuberculosis and Chest Cancer published by the Chinese Tuberculosis Association. Expert consensus on the diagnosis and treatment of retreatment of pulmonary tuberculosis[J]. Chin J Antitubercul, 2021, 43(12): 1226-1338. DOI: 10.3969/j.issn.1000-6621.2021.12.002. [8] 中国防痨协会. 流动人口肺结核患者管理指南[J]. 新发传染病电子杂志, 2021, 6(1): 7-12. DOI: 10.19871/j.cnki.xfcrbzz.2021.01.002.Chinese Antituberculosis Association. Guidelines for the management of tuberculosis patients in floating population[J]. Electronic Journal of Emerging Infectious Diseases, 2021, 6(1): 7-12. DOI: 10.19871/j.cnki.xfcrbzz.2021.01.002. [9] 杨思晨. 肺结核患者遵医行为的影响因素及干预对策研究进展[J]. 内科, 2018, 13(1): 55-58. DOI: 10.16121/j.cnki.cn45-1347/r.2018.01.17.Yang SC. Research progress on influencing factors and intervention measures of compliance behavior in patients with pulmonary tuberculosis[J]. Internal Medicine, 2018, 13(1): 55-58. DOI: 10.16121/j.cnki.cn45-1347/r.2018.01.17.